Bacchus D to be sold as quasi-drug

Published: 2011-10-10 06:58:00

Updated: 2011-10-10 06:58:00

The Korea Food and Drug Administration says that Dong-A Pharmaceutical’s Bacchus-D was reclassified into one of the quasi-drugs last month, although the company has pledged to provide Bacchus-F to retailers and Bacchus-D to pharmacies.

Ending weeks of silence over whether it would provide Bacc...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK